非肌肉浸润性膀胱癌管理的最新进展
Update on the management of non-muscle invasive bladder cancer.
作者信息
Aldousari Saad, Kassouf Wassim
机构信息
Division of Urology, McGill University Health Centre, Montréal, QC.
出版信息
Can Urol Assoc J. 2010 Feb;4(1):56-64. doi: 10.5489/cuaj.777.
Abstract
Non-muscle invasive bladder cancer (NMIBC) is a heterogeneous population of tumours accounting for 80% of bladder cancers. Over the years, the management of this disease has been changing with improvements in results and outcomes. In this review, we focus on the latest updates on the management of NMIBC.
摘要
非肌层浸润性膀胱癌（NMIBC）是一类异质性肿瘤群体，占膀胱癌的80%。多年来，随着治疗效果和预后的改善，该疾病的管理方式一直在发生变化。在本综述中，我们重点关注非肌层浸润性膀胱癌管理方面的最新进展。
相似文献
1
Update on the management of non-muscle invasive bladder cancer.非肌肉浸润性膀胱癌管理的最新进展
Can Urol Assoc J. 2010 Feb;4(1):56-64. doi: 10.5489/cuaj.777.
2
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.前瞻性评估膀胱影像报告和数据系统（VI-RADS）及其对高危非肌肉浸润性膀胱癌患者重复经尿道切除术候选者管理的临床影响。
Eur Urol. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5.
3
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
4
Non-Muscle Invasive Bladder Cancer: A Review of the Current Trend in Africa.非肌肉浸润性膀胱癌：非洲当前趋势综述
World J Oncol. 2019 Jun;10(3):123-131. doi: 10.14740/wjon1210. Epub 2019 Jun 29.
5
Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.欧洲泌尿外科学会指南与非肌肉浸润性膀胱癌管理日常实践之间的差异：一项欧洲调查的结果。
Eur Urol Focus. 2019 Jul;5(4):681-688. doi: 10.1016/j.euf.2017.09.002. Epub 2017 Oct 23.
6
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.1973 年和 2004/2016 年世界卫生组织分级分类系统在非肌肉浸润性膀胱癌中的预后性能和可重复性：欧洲泌尿外科学会非肌肉浸润性膀胱癌指南小组系统评价。
Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28.
7
Review on gender differences in non-muscle invasive bladder cancer.非肌层浸润性膀胱癌的性别差异综述
Transl Androl Urol. 2019 Feb;8(1):12-20. doi: 10.21037/tau.2018.11.06.
8
Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.免疫组织化学生物标志物在非肌肉浸润性膀胱癌和肌肉浸润性膀胱癌中的预后意义。
Mini Rev Med Chem. 2020;20(12):1133-1152. doi: 10.2174/1389557516666160512151202.
9
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术（re-cTURBT）作为pT1期高级别（HG）疾病复发和进展的风险指标是否有用？一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
10
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2013 年更新版。
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
引用本文的文献
1
PAQR4: A Critical Senescence-Related Gene Influencing Immune Evasion and Metastasis in Bladder Urothelial Carcinoma.
Hum Mutat. 2025 Sep 12;2025:2227219. doi: 10.1155/humu/2227219. eCollection 2025.
2
Hydrogel technologies in andrology: advances in research and prospective applications.男性学中的水凝胶技术：研究进展与潜在应用
Front Pharmacol. 2025 Jul 28;16:1635007. doi: 10.3389/fphar.2025.1635007. eCollection 2025.
3
Tolerability and efficacy of induction Bacillus Calmette-Guérin for non-muscle invasive bladder cancer.卡介苗诱导治疗非肌层浸润性膀胱癌的耐受性和疗效
Bladder (San Franc). 2025 Apr 11;12(2):e21200031. doi: 10.14440/bladder.2024.0051. eCollection 2025.
4
From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.从实验室到临床应用：免疫检查点抑制剂在非肌层浸润性膀胱癌治疗中的兴起
Cancers (Basel). 2025 Mar 28;17(7):1135. doi: 10.3390/cancers17071135.
5
Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature.非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术（TURBT）的最新进展与新兴创新：当前文献综述
Res Rep Urol. 2025 Mar 14;17:69-85. doi: 10.2147/RRU.S386026. eCollection 2025.
6
Effect of hypoxia-induced mIL15 expression on expansion and memory progenitor stem-like TILs .缺氧诱导的mIL15表达对扩增及记忆祖细胞样肿瘤浸润淋巴细胞的影响
Front Immunol. 2024 Nov 22;15:1450245. doi: 10.3389/fimmu.2024.1450245. eCollection 2024.
7
Metastasis development in non-muscle-invasive bladder cancer.非肌层浸润性膀胱癌中的转移发展
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
8
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol.日间 TURBT 患者的 ERAS：提高膀胱癌护理水平（EMBRACE）随机对照试验方案。
BMJ Open. 2024 Jun 10;14(6):e076763. doi: 10.1136/bmjopen-2023-076763.
9
BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies.卡介苗在非肌层浸润性膀胱癌治疗期间引起的下尿路症状——机制与管理策略
Front Neurosci. 2024 Jan 8;17:1327053. doi: 10.3389/fnins.2023.1327053. eCollection 2023.
10
MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer.基于 MRI/RNA-Seq 的放射基因组学和人工智能在肌肉浸润性膀胱癌更准确分期中的应用。
Int J Mol Sci. 2023 Dec 20;25(1):88. doi: 10.3390/ijms25010088.
本文引用的文献
1
Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.卡介苗膀胱灌注治疗膀胱原位癌的临床疗效
Int J Urol. 2008 Apr;15(4):309-13. doi: 10.1111/j.1442-2042.2008.02012.x.
2
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.非肌层浸润性膀胱癌（Ta、T1和Tis期）管理指南：2007年更新版
J Urol. 2007 Dec;178(6):2314-30. doi: 10.1016/j.juro.2007.09.003.
3
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.非肌层浸润性膀胱癌的膀胱内药物治疗：对当前可用药物、治疗方案及长期结果的批判性分析
Eur Urol. 2008 Jan;53(1):45-52. doi: 10.1016/j.eururo.2007.08.015. Epub 2007 Aug 20.
4
Natural history, recurrence, and progression in superficial bladder cancer.浅表性膀胱癌的自然病史、复发及进展
ScientificWorldJournal. 2006 Mar 27;6:2617-25. doi: 10.1100/tsw.2006.404.
5
A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.一项关于六氨基乙酰丙酸荧光膀胱镜检查与白光膀胱镜检查用于检测膀胱癌患者浅表乳头状病变的多中心III期比较研究。
J Urol. 2007 Jul;178(1):62-7. doi: 10.1016/j.juro.2007.03.034. Epub 2007 May 11.
6
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.一项多中心随机前瞻性试验，比较三种用于中危浅表性膀胱癌的膀胱内辅助治疗方法：低剂量卡介苗（27毫克）对比极低剂量卡介苗（13.5毫克）对比丝裂霉素C。
Eur Urol. 2007 Nov;52(5):1398-406. doi: 10.1016/j.eururo.2007.04.062. Epub 2007 Apr 27.
7
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.使用5-氨基乙酰丙酸诱导荧光诊断对浅表性膀胱癌复发风险进行临床相关降低：前瞻性随机研究的8年结果
Urology. 2007 Apr;69(4):675-9. doi: 10.1016/j.urology.2006.12.023.
8
Cancer statistics, 2007.2007年癌症统计数据。
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66. doi: 10.3322/canjclin.57.1.43.
9
The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.氧氟沙星对浅表性膀胱癌患者卡介苗诱导毒性的影响：一项随机、前瞻性、双盲、安慰剂对照、多中心研究的结果。 （注：原文中“of ofloxacin”多了一个of）
J Urol. 2006 Sep;176(3):935-9. doi: 10.1016/j.juro.2006.04.104.
10
Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.卡介苗联合α-2B干扰素用于降低浅表性膀胱癌复发的全国多中心II期试验的最终结果。
Urol Oncol. 2006 Jul-Aug;24(4):344-8. doi: 10.1016/j.urolonc.2005.11.026.
Zotero 插件